Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 10;19(1):9.
doi: 10.1186/s12959-021-00261-2.

A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals

Imad Hajj  1 , Mahmoud Al-Masri  2 , Kaldoun Bashaireh  3 , Mohammed Bani Hani  4 , Shadi Hamouri  4 , Joe Khouzami  5 , Nisrine Sabra  5 , Chahine Fadel  5
Affiliations

A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals

Imad Hajj et al. Thromb J. .

Abstract

Background: There is a growing body of evidence showing substantial underuse of appropriate venous thromboembolism (VTE) prophylaxis in patients at risk. In the present study, our goal was to assess the current practices in the use rate of VTE prophylaxis among hospitalized patients in Jordan and Lebanon.

Methods: A cross-sectional, multicenter, observational study was conducted on 40 centers across Lebanon and Jordan. We included patients who were admitted to the participating hospitals for the treatment of a serious medical or surgical illness. The patients' records were screened for the fulfillment of inclusion/exclusion criteria during a single assessment visit. The proportion of medical and surgical patients who were at risk of VTE and the thrombo-prophylactic measures employed by physicians for these patients were assessed according to the American College of Chest Physicians (ACCP 2016) guidelines.

Results: The present study included 704 patients (400 from Jordan and 304 from Lebanon) with a mean age of 54.9 ± 17.5 years. Almost 59% of the patients received prophylaxis treatment in form of pharmacological anticoagulant prophylaxis and/or mechanical prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant for VTE prophylaxis in 366 out of the total 704 (51.9%) patients in the analysis cohort. Two hundred and sixteen patients (52, 95% confidence interval [47.1-56.9%]) received appropriate prophylactic agents out of 415 patients who were eligible for prophylaxis according to the ACCP 2016 guidelines. On the other hand, 199 (72.1, 95% confidence interval [66.4-77.3%) patients received prophylaxis out of 276 ineligible patients. The rate of compliance to guidelines showed wide variations according to the type of hospital, specialty, and the patients' age. The multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis (odds ratio [OR] 1.05, P < 0.001).

Conclusion: The rates of the appropriate use of VTE prophylaxis are low in Lebanon and Jordan. There is a lack of compliance to guidelines for VTE prophylaxis use for hospitalized patients in both countries.

Keywords: ACCP guideline; VTE prophylaxis; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
VTE prophylaxis out of the patients eligible for prophylaxis according to ACCP guidelines. ACCP; American College of Chest Physicians, VTE; venous thromboembolism
Fig. 2
Fig. 2
VTE prophylaxis in surgical patients out of the patients eligible for prophylaxis according to ACCP guidelines. ACCP; American College of Chest Physicians, VTE; venous thromboembolism
See this image and copyright information in PMC

References

    1. Battinelli EM, Murphy DL, Connors JM. Venous Thromboembolism Overview. Hematology/Oncology Clinics of North America. 2012. - PubMed
    1. Martinelli I. Thrombosis and Haemostasis. 2001. Risk factors in venous thromboembolism; pp. 395–403. - PubMed
    1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE study cohort. Am J Med. 2013;126(9):832.e13–832.e21. doi: 10.1016/j.amjmed.2013.02.024. - DOI - PubMed
    1. Scheres LJJ, Lijfering WM, Cannegieter SC. Current and future burden of venous thrombosis: not simply predictable. Res Pract Thromb Haemost. 2018;2(2):199–208. doi: 10.1002/rth2.12101. - DOI - PMC - PubMed
    1. Henke PK, Pannucci CJ. Venous thromboembolism risk factor assessment and prophylaxis. Phlebology. 2010;25:219–223. doi: 10.1258/phleb.2010.010018. - DOI - PMC - PubMed

LinkOut - more resources